On January 8, 2021 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, reported that Snehal Patel, CEO of Greenwich LifeSciences, will participate in three virtual investor conferences during the week of January 11, 2021 (Press release, Greenwich LifeSciences, JAN 8, 2021, View Source [SID1234573691]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright BioConnect Conference:
The Company will be participating in the H.C. Wainwright BioConnect Conference with a virtual presentation that will be available on demand beginning at 6:00 am EST on January 11, 2021 and can be viewed here.
The virtual presentation will also be available on the Company’s website here.
Biotech Showcase 2021 Digital:
The Company will be participating in the Biotech Showcase partnering event with an on-demand presentation available to conference participants.
BIO Partnering at JPM:
The Company will be participating in the BIO partnering event at the 2021 JP Morgan Healthcare Conference.
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.